$PHVS News

Pharvaris N.V. (PHVS) Presents at 2026 HAEi Regional Conference Americas - Slideshow

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44

Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema - Slideshow

Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44

Pharvaris Could Gain Hereditary Angioedema Market Share on Deucrictibant XR Data, RBC Says

Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62

Leerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65

Pharvaris charts approval course for swelling disorder drug on Phase III win

Wells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65

RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $62